Q-omics provides the consensus-scored DPYD-IT1 profile across patient tissues and cancer cell-line models. DPYD-IT1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DPYD-IT1 is differentially expressed in 2, with the highest sampling consensus in BLCA. Additionally, DPYD-IT1 RNA expression shows 19,425 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, BLCA, and LSCC as cancer lineages where DPYD-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPYD-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPYD-IT1 survival associations across molecular data types. DPYD-IT1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPYD-IT1 RNA expression–survival associations across cancer types. High DPYD-IT1 expression shows unfavorable associations in KICH, TGCT, KIRC, COAD and UCS, but favorable associations in ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for DPYD-IT1 RNA expression.
This table summarizes DPYD-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for DPYD-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPYD-IT1 shows lower tumor expression in BLCA and higher tumor expression in LUAD. The BLCA box plot shows higher DPYD-IT1 RNA expression in normal versus tumor tissue (log2 FC = −0.190, t-test p = .005).
This table shows molecular features associated with DPYD-IT1 in patient tissues and cancer cell lines. In patient samples, DPYD-IT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
